Sec Form 3 Filing - ATAI Life Sciences B.V. @ IntelGenx Technologies Corp. - 2021-05-14

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person ATAI Life Sciences B.V. 2. Issuer Name and Ticker or Trading Symbol IntelGenx Technologies Corp. [ IGXT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) KRAUSENSTRASSE 9-10 3. Date of Earliest Transaction (MM/DD/YY) 05/14/2021 (Street) BERLIN, 2M 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, $0.00001 par value per share 37,300,000 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrant (Right to Buy) $ 0.35 ( 1 ) 05/14/2024 Common Stock, $0.00001 par value 22,380,000 ( 2 ) D Warrant (Right to Buy) ( 3 ) ( 1 ) 05/14/2024 Common Stock, $0.00001 par value 130,000,000 ( 3 ) D Warrant (Right to Buy) ( 4 ) ( 1 ) ( 4 ) Common Stock, $0.00001 par value ( 4 ) D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other ATAI Life Sciences B.V. KRAUSENSTRASSE 9-10 BERLIN, 2M X ATAI Life Sciences AG KRAUSENSTRASSE 9-10 BERLIN, 2M X Signatures /s/ Florian Brand, Chief Executive Officer of ATAI Life Sciences B.V. and ATAI Life Sciences AG 05/24/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )See Exhibit 99.1 ( 2 )See Exhibit 99.1 ( 3 )See Exhibit 99.1 ( 4 )See Exhibit 99.1

Remarks: In April 2021, ATAI Life Sciences AG was acquired by ATAI Life Sciences B.V. as a consequence of a capital increase of ATAI Life Sciences B.V. in the context of which the shareholders of ATAI Life Sciences AG contributed and transferred their shares in ATAI Life Sciences AG as a contribution in kind to ATAI Life Sciences B.V., resulting in ATAI Life Sciences AG becoming a wholly-owned subsidiary of ATAI Life Sciences B.V. and the shareholders of ATAI Life Sciences AG becoming the shareholders of ATAI Life Sciences B.V. Accordingly, this Form 3 has been filed on behalf of ATAI Life Sciences AG and ATAI Life Sciences B.V.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.